news
5 February 2026
Milan, Italy — 27 January 2026 — IAMA Therapeutics has been awarded the Premio ScaleUp at the Carica delle 101 Awards 2026, in recognition of the […]
5 November 2025
GENOA, Italy, November 10, 2025 – IAMA Therapeutics, a clinical-stage biopharmaceutical company advancing selective NKCC1 inhibitor therapies for central nervous system (CNS) disorders, today announced the […]
16 April 2025
GENOA, Italy, April 16, 2025 — IAMA Therapeutics, a biotechnology company focused on the neuroscience drug discovery and start-up of Istituto Italiano di Tecnologia (Italian Institute […]
26 March 2025
San Diego, CA – March 26, 2025 — On Wednesday, March 26 at 2:35 p.m. PDT, Marco Borgogno, PhD, Head of Discovery at IAMA Therapeutics, will present the first public data on our investigational […]
26 November 2024
Milan, Italy — 26 November 2024 — Innovation made in Italy takes center stage once again. IAMA Therapeutics has been honored with the Premio Innovazione SEmi, the annual award bestowed by […]
24 September 2024
Milan, Italy — 21–24 September 2024 — IAMA Therapeutics is headed to the 37th European College of Neuropsychopharmacology (ECNP) Congress, Europe’s premier forum for brain research and clinical innovation. […]
26 June 2024
Vienna, Austria — 26 June 2024 — IAMA Therapeutics is in the spotlight this week at the FENS Forum 2024 (#FENS2024), Europe’s largest neuroscience meeting, taking place 25–29 June at the Messe Wien […]
11 April 2024
GENOA, Italy, April 11, 2024 — IAMA Therapeutics today announced the appointment of Federico Bolognani, MD, PhD, as Chief Medical Officer (CMO). Bringing extensive expertise in […]
19 February 2024
GENOA, Italy, February 19, 2024 — IAMA Therapeutics has successfully dosed the first two cohorts of subjects and has started dosing the third one in the […]
23 January 2024
GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
20 December 2023
GENOA, Italy, December 20, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
1 December 2023
Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies GENOA, Italy, December 1, 2023 — IAMA Therapeutics, a pharmaceutical company focused […]
2 October 2023
GENOA, Italy, October 02, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
13 September 2023
GENOA, Italy, September 13, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
10 July 2023
IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy
GENOA, Italy, July 10, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
1 June 2023
GENOA, Italy, June 1, 2023 – IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in […]
31 May 2023
13 January 2023
26 July 2022
29 June 2022
24 May 2022
31 March 2022
